"Viral Load" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
| Descriptor ID |
D019562
|
| MeSH Number(s) |
E01.370.225.875.950 E05.200.875.950 G06.920.850
|
| Concept/Terms |
Viral Load- Viral Load
- Load, Viral
- Viral Burden
- Burden, Viral
|
Below are MeSH descriptors whose meaning is more general than "Viral Load".
Below are MeSH descriptors whose meaning is more specific than "Viral Load".
This graph shows the total number of publications written about "Viral Load" by people in this website by year, and whether "Viral Load" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 7 | 8 |
| 2005 | 1 | 5 | 6 |
| 2006 | 2 | 5 | 7 |
| 2007 | 4 | 5 | 9 |
| 2008 | 1 | 7 | 8 |
| 2009 | 5 | 6 | 11 |
| 2010 | 6 | 23 | 29 |
| 2011 | 7 | 18 | 25 |
| 2012 | 5 | 16 | 21 |
| 2013 | 7 | 17 | 24 |
| 2014 | 7 | 25 | 32 |
| 2015 | 8 | 21 | 29 |
| 2016 | 4 | 24 | 28 |
| 2017 | 4 | 29 | 33 |
| 2018 | 4 | 21 | 25 |
| 2019 | 14 | 27 | 41 |
| 2020 | 14 | 24 | 38 |
| 2021 | 7 | 27 | 34 |
| 2022 | 1 | 17 | 18 |
| 2023 | 0 | 11 | 11 |
| 2024 | 6 | 9 | 15 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Load" by people in Profiles.
-
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection. Curr Opin HIV AIDS. 2025 May 01; 20(3):249-256.
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
-
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
-
95-95-95 HIV indicators among children younger than 15 years in South Africa: results from the 2017 national HIV prevalence, incidence, behaviour, and communication survey. AIDS Res Ther. 2025 Jan 14; 22(1):6.
-
Effectiveness of a task-sharing collaborative care model for the detection and management of depression among adults receiving antiretroviral therapy in primary care facilities in South Africa: A pragmatic cluster randomised controlled trial. J Affect Disord. 2025 Feb 01; 370:499-510.
-
Are social protection and food security accelerators for adolescents to achieve the Global AIDS targets? J Int AIDS Soc. 2024 Oct; 27(10):e26369.
-
Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS. 2024 Dec 01; 38(15):2073-2085.
-
Performance of an in-house multiplex PCR assay for HIV-1 drug resistance testing - A cheaper alternative. J Virol Methods. 2024 Dec; 330:115034.
-
Performance of patient-collected dried blood specimens for HIV-1 viral load testing in South Africa. AIDS. 2024 Dec 01; 38(15):2050-2055.
-
The HIV Care Cascade for Older Adults in Rural South Africa: A Longitudinal Cohort Study (2014-2019). J Acquir Immune Defic Syndr. 2024 08 01; 96(4):334-340.